


The present invention relates to the delta crystalline form of perindopril L-arginine salt of formula (I):



characterized by the following X-ray powder diffraction peaks measured using a diffractometer with a copper anticathode and expressed in terms of Bragg's angle 2 theta (°): 4.3, 11.0, 11.1, 13.2, 14.6, 16.0 and 21.9;  
and to a process for its preparation by crystallization or recrystallisation from a binary mixture of acetonitrile, ethyl acetate or methyl tertbutyl ether and dimethyl sulphoxide or a ternary mixture of acetonitrile, dimethyl sulphoxide and toluene, at a temperature higher than 20°C;  
and to pharmaceutical compositions containing it.  
The process described provides the obtaining of delta crystalline form of perindopril L-arginine salt of formula (I), possessing a high stability.

Claims: 16

Fig.: 3